CraniUS Announces FDA 510(k) Clearance for NeuroPASS 3

CraniUS Therapeutics announced that the U.S. Food and Drug Administration granted 510(k) clearance for its NeuroPASS 3 cranial drug delivery system, according to PR Newswire.

The announcement describes the clearance as the company’s second FDA 510(k) clearance in six weeks for the NeuroPASS platform. PR Newswire also reported that CraniUS earned a U.S. patent for the NeuroPASS 3 cranial drug delivery system.

NeuroPASS 3 regulatory update

The reported FDA action is a regulatory milestone for CraniUS Therapeutics and its NeuroPASS platform. The company identified NeuroPASS 3 as a cranial drug delivery system in its announcement.

For professionals following medical, pharmaceutical, and biotech commercial developments, the event centers on a 510(k) clearance for a named product within the NeuroPASS platform. The release combines the regulatory update with a patent announcement involving the same system.

What PR Newswire reported

• CraniUS Therapeutics announced FDA 510(k) clearance for the NeuroPASS 3 cranial drug delivery system.
• The company said the clearance was its second FDA 510(k) clearance in six weeks.
• PR Newswire reported that CraniUS earned a U.S. patent for the NeuroPASS 3 cranial drug delivery system.

Commercial tracking context

The announcement offers a current reference point for teams monitoring cranial drug delivery systems and FDA regulatory activity. PR Newswire characterized the clearance and patent as a combined advance for CraniUS Therapeutics’ NeuroPASS platform.

The available report does not provide further details on the clearance, the patent, or the system’s commercial plans. The reported facts are limited to the FDA 510(k) clearance, the company’s statement regarding a second clearance in six weeks, and the U.S. patent announcement.